# **ADRC Directors' Meeting**


National Institute on Aging Virtual October 2, 2020

# **NIA Division of Neuroscience Update**

Eliezer Masliah Division of Neuroscience NIA-NIH




# **NIA Division of Neuroscience**




To support and advance research leading to better understanding of the mechanisms of brain aging and Alzheimer's Disease and related dementias





# NIA AD Translational Research Program: Diversifying the Therapeutic Pipeline


A Pipeline of Translational Research Funding Opportunities (R21/R01, U01, SBIR/STTR)





# NIA resources for data sharing in support of 2025

**NIA Program Directors:** Nina Silverberg, Cerise Elliott, Laurie Ryan, Suzana Petanceska, Lorenzo Refolo, Marilyn Miller, Dallas Anderson, Kristina McLinden



- ACTC AD Clinical Trials
   Consortium
- ADSP AD Sequencing Program
- ADGC- AD Genetics
   Consortium
- ADNI AD Neuroimaging
   Initiative
- ADRCs AD Research Centers
- AMP-AD Accelerating Medicines Partnership for AD
- MODEL-AD Model
   Organism Develop and
   Evaluation for Late-Onset
   AD
- NACC National AD Coordinating Center
- NCRAD National Centralized Repository for AD and ADRD

## **NIA Division of Neuroscience New Organization**

	Directors Office	<ul> <li>Eliezer Masliah (Director) and Jennie Larkin (Deputy Director)</li> <li>Jean Tiong-Koehler, Toni Salazar, Donna Weaver, Sarita Chapman, LaKeisha Carroll, Alexander Bracy, Chelsea Dinneny</li> </ul>
Offices	Leadership team	<ul> <li>Eliezer Masliah, Jennie Larkin, Bradley Wise, Molly Wagster, Suzana Petanceska, Laurie Ryan, Lorenzo Refolo</li> </ul>
	Strategic Development and Partnerships Office	<ul> <li>Suzana Petanceska (Director)</li> <li>Nadezda Radoja, Erika Tarver, Laurie Ryan, Jean Yuan,</li> <li>Alvin McKelvy</li> </ul>
Branches	Population Studies and Genetics Branch	<ul> <li><i>TBN Chief</i></li> <li>Dallas Anderson, Marilyn Miller, Alison Yao, Jennie Larkin, Ananya Paria, Sharna Tingle</li> </ul>
	Neurobiology of Aging and Neurodegeneration Branch	<ul> <li>Brad Wise (Chief)</li> <li>Mack Mackiewicz, Paul Barrett, Amanda M. DiBattista, Austin Yang, Lisa Opanashuk, Elizabeth A. Newman</li> </ul>
	Behavioral and Systems Neuroscience Branch	<ul> <li>Molly Wagster (Chief)</li> <li>Luci Roberts, Coryse St. Hillaire-Clarke, Devon Oskvig, Matt J Sutterer, Dave Frankowski</li> </ul>
	Translational Research Branch	<ul> <li>Lorenzo Refolo (Chief)</li> <li>Suzana Petanceska, Zane Martin, Jean Yuan, Shreaya Chakroborty,</li> <li>Ali Sharma</li> </ul>
	Clinical Interventions and Diagnostics Branch	<ul> <li>Laurie Ryan (Chief)</li> <li>Nina Silverberg, John Hsiao, Cerise Elliot, Yuan Luo, Kristina McLinden, Akanni Clarke, Grayson Donley, Alvin McKelvy</li> </ul>



## **Director's Office**



Eliezer Masliah (Director) and Jennie Larkin (Deputy Director) Jean Tiong-Koehler, Toni Salazar, Donna Weaver,



Sarita Chapman, LaKeisha Carroll, Alex Bracy, Chelsea Dinneny

## Office for Strategic Development and Partnerships

Enable an integrated approach to program development on all aspects of brain aging, Alzheimer's disease, and related dementias to accelerate therapy development and to facilitate the Division of Neuroscience's collaborations.

• NAPA milestones, AD Summit, ADBB, Public-Private Partnerships, IADRP Suzana Petanceska (Director)

Laurie Ryan Nadezda Radoja Erika Tarver Jean Yuan Alvin McKelvy





# Population Studies and Genetics Branch



Understanding the contributions of population and genetics studies in brain aging and neurodegeneration

- Trajectory of cognitive decline- MCI/AD, potential risk and protective factors
- **Morbidity/mortality-** *in general populations and race/ethnic subpopulations*
- Novel genomic elements- functional roles driving heterogeneity
- Integrated genomics- machine learning, functional genomics, harmonization
- ADSP, NIAGADS, CGAD, GCAD

# Dallas Anderson,


Damali Martin Marilyn Miller, Alison Yao, Jennie Larkin, Ananya Paria, Sharna Tingle








## Neurobiology of Aging and Neurodegeneration Branch



Understanding how the nervous system is affected by normal as well as pathological aging

- Fundamental Neuroscience- functional changes, selective vulnerability, plasticity
- Basic Science of AD/ADRD- molecular and cellular mechanisms, repair, neurovirology
- Integrative Neurobiology- changes between organ systems and the CNS
- Sleep and Biological Rhythms sleep-wake cycles/disordered biorhythmicity
- BRAIN initiative, Stem cells, human connectome, Blueprint, single cell atlas

Brad Wise (Chief) Mack Mackiewicz Amanda M. DiBattista Lisa Opanashuk Austin Yang Paul Barrett Elizabeth A. Newman Rachel Sare







# Behavioral and Systems Neuroscience Branch




Neural and psychological mechanisms underlying age-related changes in cognition, emotion, sensory and motor function

- Cognitive neuroscience- learning, memory, attention, executive function, language
- Sensory processes- visual, auditory, somatosensory, pain, vestibular
- Motor function- neuromuscular, sensory-motor, balance, and movement disorders
- Affective Neuroscience- interface between emotion and cognition
- NIH Toolbox, HEAL Initiative, Delirium, Resilience, Super-Agers

Molly Wagster (Chief) Luci Roberts Coryse St. Hillaire-Clarke Devon Oskvig Matt J Sutterer Dave Frankowski







# Translational Research Branch



Supports the spectrum of drug discovery and preclinical drug development from target discovery and validation through securing Investigational New Drug (IND)

- Target discovery and validation systems and network biology approaches
- **Drug discovery and preclinical drug development** *development of small molecules* and biologics for a diverse set of therapeutic targets
- **Drug repositioning and combination therapy development –** *integrated computational and experimental approaches*
- **Translational Infrastructure and Training –** open science consortia and centers, resources for increasing research rigor, reproducibility, and translatability
- ADDP, SBIR-STTR, Blueprint Neurotherapeutics, AMP-AD and Affiliated Consortia (M<sup>2</sup>OVE-AD, Resilience-AD, Psych-AD), MODEL- AD Consortium, TREAT-AD Centers, AD Knowledge Portal/Agora, ALzPED

Larry Refolo (Chief) Suzana Petanceska Zane Martin Jean Yuan Shreaya Chakroborty Ali Sharma





Supports research aimed at prevention, treatment, and management of individuals with or at-risk for cognitive decline, AD/ADRD


- **Biomarkers** diagnostic procedures instruments, imaging, fluid and digital biomarkers, and clinical and neuropsychological instruments for diagnosis
- Pharmacological and non-pharmacological clinical trials- Phases I-III, small molecules, biologics, combination therapies, neurostimulation, behavioral, lifestyle Clinical Trials Infrastructure and Training
- ADRCs, NACC, NCRAD, ADNI, ACTC, DIAN, DIAN-TU, ABC-DS

Laurie Ryan (Chief) Nina Silverberg John Hsiao Cerise Elliot Yuan Luo Kristina McLinden Akanni Clarke Grayson Donley Alvin McKelvy





## **NIA Division of Neuroscience Collaborations**




NINDS, NHLBI, NIMH, NICHD, NIDDK, NIDCD, NICHD, others

Cross-cutting: DISPARITIES, DIVERSITY, TRAINING




# **Understanding AD in the context of Aging**





## New FOAs in Aging related cellular and molecular mechanisms in AD/ADRD FY2020



https://www.nia.nih.gov/approved-concepts#Sept2020



# Recent conflicting reports on adult human neurogenesis raise controversy.

#### Published: 07 March 2018

#### Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults

Shawn F. Sorrells, Mercedes F. Paredes, Arantxa Cebrian-Silla, Dashi Qi, Kevin W. Kelley, David James, Simone Mayer, Julia C Edward F. Chang, Antonio J. Gutierrez, Arnold R. Kriegstein, G Michael C. Oldham, Eric J. Huang, Jose Manuel Garcia-Verdug & Arturo Alvarez-Buylla 🖂

*Nature* **555**, 377–381(2018) Cite this article

LETTERS

https://doi.org/10.1038/s41591-019-0375-9

Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease

nature

medicine

Elena P. Moreno-Jiménez<sup>1,2,3,6</sup>, Miguel Flor-García<sup>1,2,3,6</sup>, Julia Terreros-Roncal<sup>1,2,3,6</sup>, Alberto Rábano<sup>4</sup>, Fabio Cafini<sup>5</sup>, Noemí Pallas-Bazarra<sup>10,1,3</sup>, Jesús Ávila<sup>1,3</sup> and María Llorens-Martín<sup>0,1,2,3\*</sup>

## Is Alzheimer's Disease a Neurogenesis Disorder?

Se Hoon Choi<sup>1</sup> and Rudolph E. Tanzi<sup>1,\*</sup>

<sup>1</sup>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown,

MA 02129, USA

\*Correspondence: tanzi@helix.mgh.harva https://doi.org/10.1016/j.stem.2019.06.00




#### Dual Perspectives **5**0

#### Does Adult Neurogenesis Occur in the Human Brain?

Presenters: Arturo Alvarez-Buylla, PhD; Maria Llorens-Martin, PhD

#### NIA Workshop on Neurogenesis and Aging March 16-17, 2020 Bethesda MD (VIRTUAL) NIH leads- Molly Wagster, Brad Wise, Amanda Dibattista, Matt Sutterer





#### NIA Workshop on Neurogenesis and Aging March 16-17, 2020 Bethesda MD (VIRTUAL) NIH leads- Molly Wagster, Brad Wise, Amanda Dibattista, Matt Sutterer

#### Session I. Neurogenesis in the Adult Human Brain.


- Hippocampal neurogenesis linked cognitive deficits and AD
- Solving human neurogenesis in vivo toward therapy of brain disorders


#### Session II. Regulation of Neurogenesis in the Aging Brain.


- Regulation of neural stem cell aging with single cell
- Enhanced plasticity of new neurons in the hippocampus
- Blood-borne regulators of the hippocampal neurogenic niche

#### Session III. Functional Significance of Adult Neurogenesis.

- Blood: at the interface of aging and adult neurogenesis
- Re-engineering and Rejuvenating aging memory circuits
- Harnessing Neurogenesis to Improve Pattern Separation in Aging







National Institute on Aging

#### NIA Workshop on Neurogenesis and Aging March 16-17, 2020 Bethesda MD (VIRTUAL) NIH leads- Molly Wagster, Brad Wise, Amanda Dibattista, Matt Sutterer

#### **Develop Tools and Resources.**

Develop new genetic and molecular markers for human neurogenesis.

Establish new models to study adult neurogenesis (e.g., non-mouse animal models, organoids, computational models), and identify species differences. Improve live imaging approaches for adult neurogenesis.

### **Establish New Collaborations.**

Create multi-laboratory consortia to establish "virtual labs" across fields.

## **Evaluate the Costs and Benefits to Increased Neurogenesis.**

Test the impact of new neurons on circuits and behavior.

Collectively evaluate the neurogenic niche.

Evaluate the ideal balance of neurogenesis and mature neuron maintenance in humans.



## NIA FOAs investigating the cross talk between <u>pathogens</u> and aging and AD/ADRD research




#### Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns



David M. Asher, MD, Ermias Belay, MD, Eileen Bigio, MD, Sebastian Brandner, MD,
Scott A. Brubaker, BA, Byron Caughey, PhD, Brychan Clark, MD, Inger Damon, MD, PhD,
Marc Diamond, MD, Michelle Freund, PhD, Bradley T. Hyman, MD, PhD, Mathias Jucker, PhD,
C. Dirk Keene, MD, PhD, Andrew P. Lieberman, MD, PhD, Miroslaw Mackiewicz, PhD,
Thomas J. Montine, MD, PhD, Susan Morgello, MD, Creighton Phelps, PhD, Jiri Safar, MD, PhD,
Julie A. Schneider, MD, MS, Lawrence B. Schonberger, MD, MPH, Christina Sigurdson, DVM, PhD,
Nina Silverberg, PhD, John Q. Trojanowski, MD, PhD, and Matthew P. Frosch, MD, PhD







## Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on COVID-19




#### Notice Number: NOT-AG-20-022

Key Dates Release Date: April 2, 2020

First Available Due Date: April 06, 2020 Expiration Date: May 01, 2021

#### Related Announcements



PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) NOT-AG-20-031

Wesley Ely, 3R01AG058639-02S1 - Evaluate if hospitalized adult COVID-19 survivors have a high burden of Post-Intensive Care Syndrome (PICS)-related AD, PTSD, and depression at 6-months. Secondarily, we will also determine if hydroxychloroquine versus placebo improves these outcomes

**Eric Reiman- 3P30AG019610-20S1** - Neuropathological consequences of CNS SARS-CoV-2 in infected humans. investigations of 100 or more consecutive autopsies spanning the pandemic period.

**Panagiotis Roussos– 3R01AG065582-01S1 -** This supplement proposes to evaluate the molecular and neuropathological effects of SARS-CoV-2 in neurons and glial cells

**Todd Golde – 3U01AG046139-08S1 -** This supplement proposes to assess the potential mechanisms for the highly divergent immune responses to the SARS-CoV-2 infection

**Suzanne Craft – 3P30AG049638-05S2 - Impact** of COVID-19 related social distancing and stress on individuals with cognitive impairment as compared to older adults with normal cognition in the WF ADRC center cohort.







FUNDING

FUNDING

**İİ** 

xpressic in brain 

## **Concept Approvals:**

https://www.nia.nih.gov/approved-concepts

## **General FOAs:**

https://www.nia.nih.gov/research/funding

# Alzheimer's Disease and Related Dementias FOAs:

http://www.nia.nih.gov/AD-FOAs



# **NIA-** Division of Neuroscience

https://www.nia.nih.gov/research/dn

